Call for Abstract
Scientific Program
2nd International Conference and Exhibition on Pharmacovigilance & Clinical Trials, will be organized around the theme “Reviving Strategies for Safer Drug Development”
Pharmacovigilance-2013 is comprised of 11 tracks and 52 sessions designed to offer comprehensive sessions that address current issues in Pharmacovigilance-2013.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Role of pharmacovigilance in health regulation
- Track 1-2International collaboration and new pharmacovigilance legislation
- Track 1-3Role of pharma industries in the improvement of pharmacovigilance system
- Track 1-4Fatality of pharmacovigilance failure
- Track 1-5Detection and evaluation of drug safety signals
- Track 1-6Role of pharmacovigilance in health regulation
- Track 1-7International collaboration and new pharmacovigilance legislation
- Track 2-1Data collection and quality control
- Track 2-2Alternative trials design and models
- Track 2-3Multi center trials and monitoring
- Track 2-4Data collection and quality control
- Track 2-5Alternative trials design and models
- Track 2-6Multi center trials and monitoring
- Track 3-1Emerging technology in clinical trials
- Track 3-2Recent clinical trials on Parkinson
- Track 3-3Clinical trials on cancer
- Track 3-4Applications of biomarkers in clinical trials
- Track 4-1Assessing and reporting adverse drug reactions
- Track 4-2Reduction of adverse drug reaction by nanotechnology
- Track 4-3Expected and un-expected drug reactions and its reporting
- Track 4-4Drugs in human pregnancy and nursing
- Track 4-5Pharmacotherapy and Pharmacogenomics
- Track 4-6Post marketing reports on adverse effects
- Track 5-1Advances of pharmacokinetic interactions
- Track 5-2Advances of pharmacodynamic interactions
- Track 5-3Drug and substance abuse
- Track 5-4Drug-drug interactions
- Track 5-5Pharmacoenvironmentology
- Track 6-1Pharmacy practice and its guidelines
- Track 6-2Challenges in compounding and dispensing practice
- Track 6-3Drug toxicity and drug safety measures
- Track 6-4Pharmacoepidemiology of drug shortages
- Track 7-1Information technology in pharmacovigilance and promoting companies
- Track 7-2Review of softwares used in pharmacovigilance and clinical trials
- Track 7-3Risk communication: Interface between pharmacovigilance, sales and marketing
- Track 7-4Risk management versus recent market withdrawal
- Track 7-5Monitoring unlicensed, off labels and orphan drugs
- Track 8-1Guidelines for clinical research and its statistics
- Track 8-2Advanced Information technology in clinical trials and promoting companies
- Track 8-3Data mining concepts and techniques
- Track 9-1Strategic development towards FDA approval
- Track 9-2Advances in changing pharmacovigilance regulation system
- Track 9-3Post market product surveillances
- Track 10-1Role of pharmacovigilance and pharmacoepidemiology in risk management
- Track 10-2Good reporting practice and adverse event reports
- Track 10-3Signal investigation via observational studies
- Track 10-4Interpreting safety signals
- Track 10-5Randomized clinical trials
- Track 11-1Unique theraputic approaches
- Track 11-2Effect of treatment on patient
- Track 11-3Cancer case report
- Track 11-4Cardiovascular trials case report